



For further information please contact:

Cellzome AG
Tim Edwards
Chief Executive Officer
Tel: +49-6221-137 57-100
press@cellzome.com

Hogarth Partnership
Melanie Toyne-Sewell / John Olsen
Tel: +44 (0) 207 357 9477

Press Release

Cellzome Announces Expansion of Pathway Collaboration

Boston, USA, 26 July 2005 – Cellzome Inc. announced today that its research collaboration with Novartis has been expanded. This expansion is in line with the terms of the original agreement between the two companies.

During the past year, Cellzome has mapped the protein networks of several different signalling pathways implicated in various therapeutic areas. Many relevant protein interactors have been identified in each of the pathways, leading to a more thorough understanding of the molecular basis of the underlying diseases and novel target candidates. In addition, Cellzome has characterised several Novartis' compounds, using its chemical proteomics methodology. The additional effort will be focused on providing more in depth functional analyses of target candidates and signalling aspects of the disease pathways.

Tim Edwards, Cellzome's CEO, said: "This collaboration is working well; both teams are learning from each other and creating novel intellectual property. We continue to leverage our technology platform to create drug discovery opportunities for Novartis, and for ourselves."

In September 2004, Cellzome and Novartis entered into this collaboration that combines Cellzome's experience in chemical proteomics and pathway mapping with Novartis' insights into particular disease pathways and its expertise in sensitized cellular screens. The companies are charting the physical and functional protein maps of key cellular pathways of a variety of diseases, with the potential to select the best protein targets within these pathways for the development of new drug candidates. Cellzome's chemical proteomics expertise is also helping identify the role of active Novartis compounds in disease and their potential side effects, and thus improving the understanding of how these potential drugs might behave in man. The work is being conducted between Cellzome's Heidelberg operations and Novartis' Developmental and Molecular Pathways group based in Cambridge MA. Novartis has made a substantial equity investment in Cellzome Inc. and contributes research funding for two years with the option of extending the collaboration for a further two years. There are also lead compound development options for both companies in exchange for licenses, milestone payments and royalties.

About Cellzome Inc.

Cellzome is a private drug discovery company with world-class, proprietary proteomics technology for target and lead identification, and a drug discovery program in Alzheimer's disease. The technology provides an understanding of the molecular basis of disease and helps to identify the role of active compounds and their possible side effects, and thus provides insight into how potential drugs might behave in man. The drug discovery program is directed towards the treatment of Alzheimer's Disease by preventing the formation of toxic amyloid species in the brain, and is partnered with Johnson & Johnson.

Cellzome's strategy is to commercialise its assets and technology through building its own pipeline of clinical products and through collaboration with leading pharmaceutical partners. The company is intent on securing and maintaining strategic partnerships with leading pharmaceutical companies for revenue generation and technological advantage. To date Cellzome has signed partnerships with Johnson & Johnson PRD; Bayer Healthcare; a large pan-therapeutic collaboration with Novartis (September 2004); and a drug discovery collaboration in Alzheimer's Disease with Johnson & Johnson (March 2005).

Cellzome is intent on developing both organically and through merger or acquisition. The company is domiciled in the US and employs about 75 people at its facilities in Cambridge, UK and Heidelberg, Germany. To learn more about Cellzome, please visit the website: www.cellzome.com